Text Size
34 studies found for:    " August 13, 2008":" September 12, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Modify this search | How to Use Search Results

Show Display Options
Download search resultsDownload the search results for:
" August 13, 2008":" September 12, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION] (34 records)
Need help? See Downloading Content for Analysis
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.
Conditions: HIV Infection;   Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 10 mg oral solution;   Drug: GSK1265744 5 mg tablet
2 Completed TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.
Conditions: HIV;   AIDS;   Fungal Infection
Intervention: Drug: TMC125
3 Completed IMARA, Adapting SiHLE for Detained African American Adolescent Females
Condition: HIV Infections
Intervention: Behavioral: IMARA HIV Prevention Intervention
4 Completed Immunogenicity and Safety Trial of the HIV-1 Tat Vaccine (ISS T-002)
Condition: HIV Infections
Intervention: Biological: Tat protein
5 Completed An Affect Management Intervention for Juvenile Offenders
Condition: HIV Infections
Interventions: Behavioral: Affect Management;   Behavioral: General Health Promotion
6 Completed Effect of an Online Video-Based Intervention to Increase HIV Testing in Men Who Have Sex With Men in Peru
Condition: HIV Infections
Interventions: Device: HIV-testing motivational videos;   Device: Standard public health text
7 Completed Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS
Conditions: HIV Infections;   Fatigue
Intervention: Drug: Armodafinil
8 Completed
Has Results 		BRAVO: Background Regimen of Raltegravir on Virologic Outcome
Condition: HIV Infections
Intervention: Drug: raltegravir
9 Completed Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients
Condition: HIV Infections
Intervention: Drug: lopinavir/ritonavir and raltegravir
10 Completed
Has Results 		Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women
Condition: HIV Infections
Intervention: Drug: Raltegravir
11 Unknown † Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects
Condition: HIV Infections
Intervention: Drug: Raltegravir and Abacavir/Lamivudine
12 Completed Affect Management Intervention for Early Adolescents Wtih Mental Health Problems
Condition: HIV Infections
Interventions: Behavioral: Affect Management;   Behavioral: General Health Promotion
13 Completed Surveillance and Medical Help for HIV-infected Intravenous Drug Users in and Out of Prison
Condition: HIV Infections
Intervention:
14 Completed Attitudes and Beliefs and the Steps of HIV Care
Condition: Human Immunodeficiency Virus Infections
Intervention: Behavioral: Questionnaire
15 Unknown † Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment
Conditions: HIV;   AIDS;   Tuberculosis
Interventions: Drug: Simultaneous ARV and antiMTB;   Drug: Deferred RV and antiMTB treatment
16 Active, not recruiting Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine
Condition: HIV-1 Infection
Intervention: Drug: FTC
17 Unknown † Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment
Condition: HIV Infections
Intervention: Drug: Raltegravir and Atazanavir
18 Completed Assessment of Cytokine Values in Serum and by RT-PCR in HIV-1 Individuals With and Without HAART
Condition: HIV Infections
Intervention:
19 Completed
Has Results 		Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
Conditions: HIV Infections;   HSV-2 Genital Herpes
Intervention: Drug: 3% SPL7013 Gel (VivaGel)
20 Completed Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults
Conditions: Cholera;   Vibrio Infections;   Diarrhea
Interventions: Biological: CholeraGarde®;   Biological: Placebo
To Top

Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results
† Indicates status has not been verified in more than two years